Q-omics provides the consensus-scored RTP1 profile across patient tissues and cancer cell-line models. RTP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RTP1 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, RTP1 RNA expression shows 9,635 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where RTP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTP1 survival associations across molecular data types. RTP1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTP1 RNA expression–survival associations across cancer types. High RTP1 expression shows unfavorable associations in KIRC, THYM, KIRP and KICH, but favorable associations in BLCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RTP1 RNA expression.
This table summarizes RTP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RTP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTP1 shows lower tumor expression in PRAD and KICH and higher tumor expression in LUSC and LIHC. The LUSC box plot shows higher RTP1 RNA expression in tumor versus normal tissue (log2 FC = +0.238, t-test p = .002).
This table shows molecular features associated with RTP1 in patient tissues and cancer cell lines. In patient samples, RTP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RTP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
